Company profile ZNTL
There is not enough data for Zentalis Pharmaceuticals - clinical stage biopharmaceutical company to provide analysis
There is not enough data for Zentalis Pharmaceuticals - clinical stage biopharmaceutical company to provide correlation calculation
There is not enough data for Zentalis Pharmaceuticals - clinical stage biopharmaceutical company to provide analysis
There is not enough data for Zentalis Pharmaceuticals login to provide analysis
There is not enough data for Zentalis Pharmaceuticals login to provide correlation calculation
There is not enough data for Zentalis Pharmaceuticals login to provide analysis
There is not enough data for ZN-c3 clinical trial to provide analysis
There is not enough data for ZN-c3 clinical trial to provide correlation calculation
There is not enough data for ZN-c3 clinical trial to provide analysis
After 39 days of this quarter the interest is at 34.0. Based on that we can calculate that during remaining 52 days it will total up to 79.0. WEE1 inhibitor expected interest is significantly higher compared to previous quarter (+79.5%) and same quarter last year (+92.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 24 | 240 900.0% QoQ | 27 -88.8% QoQ | 113 318.5% QoQ |
| 2020 | 0 -100.0% YoY -100.0% QoQ | 79 -67.1% YoY inf% QoQ | 97 259.3% YoY 22.8% QoQ | 48 -57.5% YoY -50.5% QoQ |
| 2021 | 154 inf% YoY 220.8% QoQ | 223 182.3% YoY 44.8% QoQ | 103 6.2% YoY -53.8% QoQ | 21 -56.2% YoY -79.6% QoQ |
| 2022 | 15 -90.3% YoY -28.6% QoQ | 61 -72.6% YoY 306.7% QoQ | 102 -1.0% YoY 67.2% QoQ | 171 714.3% YoY 67.6% QoQ |
| 2023 | 41 173.3% YoY -76.0% QoQ | 102 67.2% YoY 148.8% QoQ | 166 62.7% YoY 62.7% QoQ | 44 -74.3% YoY -73.5% QoQ |
| 2024 | 34 -17.1% YoY -22.7% QoQ | - | - | - |
The average 5 years interest of WEE1 inhibitor was 7.15 per week. The last year interest of WEE1 inhibitor compared to the last 5 years has changed by -1.82%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -9.65%.
After 39 days of this quarter the interest is at 50.0. Based on that we can calculate that during remaining 52 days it will total up to 117.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 219 | 185 -15.5% QoQ | 97 -47.6% QoQ | 163 68.0% QoQ |
| 2020 | 90 -58.9% YoY -44.8% QoQ | 293 58.4% YoY 225.6% QoQ | 193 99.0% YoY -34.1% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2021 | 180 100.0% YoY inf% QoQ | 103 -64.8% YoY -42.8% QoQ | 214 10.9% YoY 107.8% QoQ | 207 inf% YoY -3.3% QoQ |
| 2022 | 226 25.6% YoY 9.2% QoQ | 111 7.8% YoY -50.9% QoQ | 287 34.1% YoY 158.6% QoQ | 120 -42.0% YoY -58.2% QoQ |
| 2023 | 135 -40.3% YoY 12.5% QoQ | 219 97.3% YoY 62.2% QoQ | 184 -35.9% YoY -16.0% QoQ | 114 -5.0% YoY -38.0% QoQ |
| 2024 | 50 -63.0% YoY -56.1% QoQ | - | - | - |
The average 5 years interest of small molecule therapeutics was 12.99 per week. The last year interest of small molecule therapeutics compared to the last 5 years has changed by -7.47%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -5.87%.
After 34 days of this quarter the interest is at 422.0. Based on that we can calculate that during remaining 58 days it will total up to 1142.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 544 |
| 2019 | 956 75.7% QoQ | 951 -0.5% QoQ | 914 -3.9% QoQ | 975 79.2% YoY 6.7% QoQ |
| 2020 | 990 3.6% YoY 1.5% QoQ | 814 -14.4% YoY -17.8% QoQ | 936 2.4% YoY 15.0% QoQ | 929 -4.7% YoY -0.7% QoQ |
| 2021 | 869 -12.2% YoY -6.5% QoQ | 915 12.4% YoY 5.3% QoQ | 951 1.6% YoY 3.9% QoQ | 917 -1.3% YoY -3.6% QoQ |
| 2022 | 886 2.0% YoY -3.4% QoQ | 897 -2.0% YoY 1.2% QoQ | 859 -9.7% YoY -4.2% QoQ | 860 -6.2% YoY 0.1% QoQ |
| 2023 | 947 6.9% YoY 10.1% QoQ | 946 5.5% YoY -0.1% QoQ | 900 4.8% YoY -4.9% QoQ | 422 -50.9% YoY -53.1% QoQ |
The average 5 years interest of cancer treatment was 70.41 per week. The last year interest of cancer treatment compared to the last 5 years has changed by 0.24%. The interest for cancer treatment is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by -1.58%.
After 39 days of this quarter the interest is at 267.0. Based on that we can calculate that during remaining 52 days it will total up to 623.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 306 | 412 34.6% QoQ | 434 5.3% QoQ | 380 -12.4% QoQ |
| 2020 | 401 31.0% YoY 5.5% QoQ | 417 1.2% YoY 4.0% QoQ | 435 0.2% YoY 4.3% QoQ | 471 23.9% YoY 8.3% QoQ |
| 2021 | 435 8.5% YoY -7.6% QoQ | 384 -7.9% YoY -11.7% QoQ | 402 -7.6% YoY 4.7% QoQ | 440 -6.6% YoY 9.5% QoQ |
| 2022 | 643 47.8% YoY 46.1% QoQ | 619 61.2% YoY -3.7% QoQ | 517 28.6% YoY -16.5% QoQ | 494 12.3% YoY -4.4% QoQ |
| 2023 | 724 12.6% YoY 46.6% QoQ | 643 3.9% YoY -11.2% QoQ | 597 15.5% YoY -7.2% QoQ | 585 18.4% YoY -2.0% QoQ |
| 2024 | 267 -63.1% YoY -54.4% QoQ | - | - | - |
The average 5 years interest of solid tumors was 38.34 per week. The last year interest of solid tumors compared to the last 5 years has changed by 25.04%. The interest for solid tumors is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 46.02%.
After 39 days of this quarter the interest is at 24.0. Based on that we can calculate that during remaining 52 days it will total up to 56.0. hematological malignancies expected interest is significantly lower compared to previous quarter (-78.0%) and same quarter last year (-77.6%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 250 | 224 -10.4% QoQ | 156 -30.4% QoQ | 91 -41.7% QoQ |
| 2020 | 229 -8.4% YoY 151.6% QoQ | 187 -16.5% YoY -18.3% QoQ | 326 109.0% YoY 74.3% QoQ | 148 62.6% YoY -54.6% QoQ |
| 2021 | 268 17.0% YoY 81.1% QoQ | 361 93.0% YoY 34.7% QoQ | 264 -19.0% YoY -26.9% QoQ | 101 -31.8% YoY -61.7% QoQ |
| 2022 | 256 -4.5% YoY 153.5% QoQ | 100 -72.3% YoY -60.9% QoQ | 458 73.5% YoY 358.0% QoQ | 180 78.2% YoY -60.7% QoQ |
| 2023 | 250 -2.3% YoY 38.9% QoQ | 105 5.0% YoY -58.0% QoQ | 294 -35.8% YoY 180.0% QoQ | 254 41.1% YoY -13.6% QoQ |
| 2024 | 24 -90.4% YoY -90.6% QoQ | - | - | - |
The average 5 years interest of hematological malignancies was 17.34 per week. The last year interest of hematological malignancies compared to the last 5 years has changed by -4.96%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 5.91%.
After 39 days of this quarter the interest is at 101.0. Based on that we can calculate that during remaining 52 days it will total up to 236.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 118 | 249 111.0% QoQ | 234 -6.0% QoQ | 203 -13.2% QoQ |
| 2020 | 262 122.0% YoY 29.1% QoQ | 128 -48.6% YoY -51.1% QoQ | 242 3.4% YoY 89.1% QoQ | 209 3.0% YoY -13.6% QoQ |
| 2021 | 426 62.6% YoY 103.8% QoQ | 251 96.1% YoY -41.1% QoQ | 114 -52.9% YoY -54.6% QoQ | 293 40.2% YoY 157.0% QoQ |
| 2022 | 283 -33.6% YoY -3.4% QoQ | 183 -27.1% YoY -35.3% QoQ | 194 70.2% YoY 6.0% QoQ | 183 -37.5% YoY -5.7% QoQ |
| 2023 | 236 -16.6% YoY 29.0% QoQ | 163 -10.9% YoY -30.9% QoQ | 213 9.8% YoY 30.7% QoQ | 212 15.8% YoY -0.5% QoQ |
| 2024 | 101 -57.2% YoY -52.4% QoQ | - | - | - |
The average 5 years interest of uterine serous carcinoma was 17.23 per week. The last year interest of uterine serous carcinoma compared to the last 5 years has changed by -12.36%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -13.81%.
There is not enough data for Cyclin E1 driven high-grade serous ovarian cancer to provide analysis
There is not enough data for Cyclin E1 driven high-grade serous ovarian cancer to provide correlation calculation
There is not enough data for Cyclin E1 driven high-grade serous ovarian cancer to provide analysis
There is not enough data for platinum-resistant ovarian cancer to provide analysis
There is not enough data for platinum-resistant ovarian cancer to provide correlation calculation
There is not enough data for platinum-resistant ovarian cancer to provide analysis
There is not enough data for relapsed or refractory osteosarcoma to provide analysis
There is not enough data for relapsed or refractory osteosarcoma to provide correlation calculation
There is not enough data for relapsed or refractory osteosarcoma to provide analysis
There is not enough data for mutant metastatic colorectal cancer to provide analysis
There is not enough data for mutant metastatic colorectal cancer to provide correlation calculation
There is not enough data for mutant metastatic colorectal cancer to provide analysis
After 39 days of this quarter the interest is at 52.0. Based on that we can calculate that during remaining 52 days it will total up to 121.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 179 | 142 -20.7% QoQ | 130 -8.5% QoQ | 163 25.4% QoQ |
| 2020 | 114 -36.3% YoY -30.1% QoQ | 88 -38.0% YoY -22.8% QoQ | 111 -14.6% YoY 26.1% QoQ | 134 -17.8% YoY 20.7% QoQ |
| 2021 | 107 -6.1% YoY -20.1% QoQ | 111 26.1% YoY 3.7% QoQ | 121 9.0% YoY 9.0% QoQ | 114 -14.9% YoY -5.8% QoQ |
| 2022 | 115 7.5% YoY 0.9% QoQ | 114 2.7% YoY -0.9% QoQ | 115 -5.0% YoY 0.9% QoQ | 113 -0.9% YoY -1.7% QoQ |
| 2023 | 119 3.5% YoY 5.3% QoQ | 149 30.7% YoY 25.2% QoQ | 126 9.6% YoY -15.4% QoQ | 130 15.0% YoY 3.2% QoQ |
| 2024 | 52 -56.3% YoY -60.0% QoQ | - | - | - |
The average 5 years interest of pancreatic cancer was 9.76 per week. The last year interest of pancreatic cancer compared to the last 5 years has changed by 2.66%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -21.9%.
There is not enough data for ZN-d5 inhibitor to provide analysis
There is not enough data for ZN-d5 inhibitor to provide correlation calculation
There is not enough data for ZN-d5 inhibitor to provide analysis
There is not enough data for B-cell lymphoma 2 to provide analysis
There is not enough data for B-cell lymphoma 2 to provide correlation calculation
There is not enough data for B-cell lymphoma 2 to provide analysis
There is not enough data for solid tumors and hematological malignancies. to provide analysis
There is not enough data for solid tumors and hematological malignancies. to provide correlation calculation
There is not enough data for solid tumors and hematological malignancies. to provide analysis